In a Nature Communications publication, Chloé Maurizy and colleagues (E. Bertrand’s team and 3 other teams from ANR consortium snoRNPASSEMBLY) have discovered a novel co-chaperone, called R2SP. It was known that macromolecular complex assembly requires dedicated machinery working with Hsp90. We and others have shown that R2TP/Hsp90 is involved in assembly of essential complexes such as snoRNPs, snRNPs, RNA polymerases … Continue reading R2TP and R2SP are co-chaperones involved in the assembly of macro-molecular complexes
Monoclonal antibodies (mAbs) are the largest class of biomedicines. Administered to neutralize and eliminate pathogens, they can also induce a lasting immune response, such as vaccination. The work of Mar Naranjo-Gomez et al., In the team “Oncogenesis and Immunotherapy” has demonstrated an unexpected role of a type of leukocytes, neutrophils, in the therapeutic efficacy of mAbs. These cells of the … Continue reading Neutrophils are essential for induction of vaccine-like effects by antiviral monoclonal antibody immunotherapies.
Acute Myeloid Leukemias (AML) are very aggressive hematological malignancies, which treatment is mostly based on intensive chemotherapies. This treatment has not significantly changed in the past 40 years and is characterized by a high relapse rate. Differentiation therapies, in particular those using all-trans retinoic acid (ATRA) are an alternative to chemotherapies. They aim at restoring the differentiation of AML cells … Continue reading Targeting SUMO to improve the efficiency of differentiation therapies in Acute Myeloid Leukemias
In their study in Cell reports, Ildem Sanli and her co-workers (Robert Feil lab) explore the epigenetic mechanisms involved in the mono-allelic expression of imprinted genes in mammals. The research focuses on a large chromosomal domain in the mouse. Besides the essential expression of a long non-coding RNA (called Meg3), also the Polycomb Repressive Complex-2 is found to be important … Continue reading Epigenetic Regulation of Imprinted Genes
TheranosMet is one of the 8 laureates in Biology & Health of the first call for research projects by MUSE (Montpellier Université d’Excellence). The 3-year MUSE program includes support for a PhD student. TheranosMet focuses on the theranostic use of RBD nanoparticles. RBDs are Receptor-Binding Domains derived from retroviruses that target nutrient transporters. RBDs that bind transporters known to play … Continue reading Marc Sitbon is a MUSE laureate for TheranosMet.